Involvement of Uric Acid Transporters in Alteration of Serum Uric Acid Level by Angiotensin II Receptor Blockers
- 708 Downloads
To examine the mechanisms of the alteration of serum uric acid level by angiotensin II receptor blockers (ARBs), the effects of ARBs on renal uric acid transporters, including OAT1, OAT3, OAT4, and MRP4, were evaluated.
Materials and Methods
Uptakes of uric acid by OAT1-expressing Flp293 cells, by Xenopus oocytes expressing OAT3 or OAT4, and by membrane vesicles from Sf9 cells expressing MRP4 were evaluated in the presence or absence of ARBs.
All ARBs inhibited uptake of uric acid or estrone-3-sulfate by OAT1, OAT3 and OAT4 in concentration dependent manners. Among them, the IC50 values of valsartan, olmesartan and pratosartan for OAT3 were comparable to clinically observed unbound maximum plasma concentration of ARBs. Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 μM. The IC50 value of losartan for MRP4 was comparable to the estimated kidney tissue concentration of losartan. No ARBs showed trans-stimulatory effects on the uptake of estrone-3-sulfate by OAT4.
Valsartan, olmesartan, and pratosartan could inhibit the OAT3-mediated uric acid secretion in clinical situations. Furthermore losartan could inhibit ATP-dependent uric acid secretion by MRP4. These effects may explain partially the alteration of serum uric acid level by ARBs.
Key wordsangiotensin II receptor blockers kidney MRP4 OAT uric acid transporter
angiotensin II receptor blocker
multidrug resistance-associated protein
organic anion transporter
serum uric acid
uric acid transporter
This study was supported in part by a Grant in Aid for Scientific Research from The Ministry of Education, Culture, Sports, Science, and Technology, Japan.
- 3.A. J. Manolis, E. Grossman, B. Jelakovic, A. Jacovides, D. C. Bernhardi, W. J. Cabrera, L. A. Watanabe, J. Barragan, N. Matadamas, A. Mendiola, K. S. Woo, J. R. Zhu, A. D. Mejia, T. Bunt, T. Dumortier, and R. D. Smith. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin. Ther. 22:1186–1203 (2000).PubMedCrossRefGoogle Scholar
- 4.W. J. Elliott, D. A. Calhoun, P. T. DeLucca, L. P. Gazdick, D. E. Kerns, and R. K. Zeldin. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin. Ther. 23:1166–1179 (2001).PubMedCrossRefGoogle Scholar
- 9.D. A. Sica and A. C. Schoolwerth. Chapter 16, Renal handling of organic anions and cations: Excretion of uric acid. In B. M. Brenner (ed.), The Kidney, 6th edn, Saunders, Philadelphia, 2000, pp. 680–700.Google Scholar
- 11.A. Enomoto, H. Kimura, A. Chairoungdua, Y Shigeta, P. Jutabha, S. H. Cha, M Hosoyamada, M. Takeda, T. Sekine, T. Igarashi, H. Matsuo, Y. Kikuchi, T. Oda, K. Ichida, T. Hosoya, K. Shimokata, T. Niwa, Y. Kanai, and H. Endou. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447–452 (2002).PubMedGoogle Scholar
- 15.R. A. M. H. van Aubel, P. H. E. Smeets, J. J. M. W. van den Heuvel, and F. G. M. Russel. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal. Physiol. 288:F327–F333 (2004).PubMedCrossRefGoogle Scholar
- 25.F. Yamashita, H. Ohtani, N. Koyabu, F. Ushigome, H. Satoh, H. Murakami, T. Uchiumi, T. Nakamura, M. Kuwano, M. Tsujimoto, and Y. Sawada. Inhibitory effect of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic transporter 4. J. Pharm. Pharmacol. 58:1499–1505 (2006).PubMedCrossRefGoogle Scholar